OHRP - OHR Pharmaceutical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

OHR Pharmaceutical, Inc.

800 Third Avenue
11th Floor
New York, NY 10022
United States

Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Dr. Jason Scott SlakterCEO, Pres & Director375.19kN/A1958
Mr. Samuel BackenrothCFO, VP of Bus. Devel. & Sec.324.12kN/A1984
Dr. Glenn L. Stoller M.D.Chief Scientific OfficerN/AN/A1964
Dr. Marlene ModiHead of Preclinical & Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


OHR Pharmaceutical, Inc., a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine in combination with Lucentis injections, which completed Phase II clinical trials for the treatment of retinal diseases, including wet form of age-related macular degeneration, retinal vein occlusion, and diabetic retinopathy. It is also developing a sustained release ocular drug delivery platform technology. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Corporate Governance

OHR Pharmaceutical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.